Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes-Reference-Cited by-同舟云学术

Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes

Published:2020-07 Issue:7 Volume:20 Page:438-444.e1
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Rhodes Joanna M.^ORCID,LoRe Vincent A.,Mato Anthony R.,Chong Elise A.,Barrientos Jacqueline C.,Gerson James N.,Barta Stefan K.,Landsburg Daniel J.,Nasta Sunita Dwivedy,Svoboda Jakub,Loren Alison W.,Schuster Stephen J.

Funder

TG Therapeutics

Abbvie

Pharmacyclics

Johnson & Johnson

Regeneron

Portola

DTRM

Acerta

AstraZeneca

Gilead

Seattle Genetics

BMS

Merck

Novartis

Celgene

Genentech

University of Pennsylvania Pharmacoepidemiology T32

Conquer Cancer Foundation Young Investigator

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference37 articles.

1. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia;Byrd;N Engl J Med,2014

2. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia;Burger;N Engl J Med,2015

3. A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

4. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL;Woyach;N Engl J Med,2018

5. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia;Byrd;N Engl J Med,2013

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How to treat a patient with psoriatic arthritis and chronic lymphocytic leukemia?;Exploration of Musculoskeletal Diseases;2024-06-20

2. Evidence-based expert consensus on clinical management of safety of Bruton's tyrosine kinase inhibitors (2024);CHINESE J CANCER RES;2024

3. Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents;Cancers;2024-05-24

4. How We Manage Patients with Indolent B-Cell Malignancies on Bruton’s Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists;Current Oncology;2023-04-18

5. A Multidisciplinary Approach to Managing BTK Inhibitor Toxicity in Lymphoma and Chronic Lymphocytic Leukemia;Interdisciplinary Cancer Research;2023